Julie Xing
APTARGROUPAbout Julie Xing
Independent director of AptarGroup, Inc. (ATR), age 56, serving since 2023 with committee work on Management Development & Compensation (MDC). She holds a PhD in biology from the Hong Kong University of Science and Technology and has deep Asia/Pacific and pharmaceutical market operating experience, including senior roles at Envista and Eli Lilly and current executive chairmanship at Mundipharma China .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Mundipharma China | Executive Chair, Board of Directors | 2022–present | Board leadership; pharma market expertise |
| Envista Holdings (NYSE: NVST) | Global SVP; President, Greater China | 2019–2022 | Regional P&L leadership; dental equipment/supplies market |
| Eli Lilly & Company | Senior Director, Global New Product Planning & Payer Marketing (Lilly Diabetes); Senior Director, Global Payer Marketing; VP Lilly China Oncology; VP Corporate & Government Affairs & Market Access (Shanghai) | 2010–2014; 2015–2019 | Global pricing, reimbursement, access; oncology leadership in China |
| Panomics & Affymetrix (acquired by Thermo Fisher) | VP & GM, APAC & Japan Operations | 2007–2010 | Regional operations; genomics tools |
| Illumina | General Manager; China President | 2005–2007 | Market entry and scaling in China for NGS |
External Roles
| Organization | Capacity | Tenure | Notes/Impact |
|---|---|---|---|
| Lee Kum Kee Group | Board Advisor | Feb 2025–present | Global consumer products; governance advisory |
| Mars, Incorporated | Board Advisor | 2019–2024 | Confectionery/petcare; board-level advisory |
| Imagine Institute | Independent Director | Current | Medical research governance |
| France 2030 | Key Contributor | Current | National innovation investment program |
Board Governance
- Independence: 9 of 10 directors independent; Xing classified as independent under NYSE standards .
- Committee assignment: Management Development & Compensation (member); MDC held 6 meetings in 2024; no interlocking relationships among members .
- Executive sessions: Independent directors meet regularly; sessions chaired by independent Board Chair (Candace Matthews) .
- Attendance: Board met 7 times in 2024; no current director attended fewer than 75% of Board and applicable committee meetings .
| Committee | Role | 2024 Meetings |
|---|---|---|
| Management Development & Compensation | Member | 6 |
Fixed Compensation (Director)
| Component | Amount (USD) | Notes |
|---|---|---|
| Annual cash retainer | $100,000 | Paid in advance post-AGM |
| MDC Committee member fee | $7,000 | Annual retainer for membership |
| Total cash (2024) | $107,000 | Per director compensation table |
| Other cash/perqs | $0 | No retirement benefits/perquisites for non-employee directors |
Performance Compensation (Director)
| Equity Award | Grant Detail | Fair Value | Vesting/Terms |
|---|---|---|---|
| Annual RSUs | 1,113 RSUs granted May 1, 2024 (non-chair) | $160,072 (per-grant fair value $143.82/share) | Subject to 2018 Plan minimum 1-year vesting; dividends/dividend equivalents not paid current; subject to same vesting as underlying awards |
No performance-conditioned awards (PSUs/options) are disclosed for non-employee directors; compensation for directors is primarily time-based RSUs under the 2018 Plan .
Other Directorships & Interlocks
- Current public company boards: None disclosed for Xing .
- Committee interlocks: None among MDC members in 2024 (SEC definition) .
- Related-party transactions: None requiring disclosure since Jan 1, 2024; Audit Committee oversees and must pre-approve any such transactions .
Expertise & Qualifications
- Domain: Pharmaceutical market expertise; pricing/reimbursement; oncology; Greater China operations .
- Regional leadership: APAC/China multi-national scaling experience .
- Education: PhD in biology (HKUST) .
- Recognition/roles: Governance and innovation contributions (Imagine Institute; France 2030) .
Equity Ownership
| Item | Amount | Notes |
|---|---|---|
| Shares beneficially owned | 2,696 | As of Mar 14, 2025 |
| RSUs vesting within 60 days | 1,113 | As of Mar 14, 2025 |
| Options | None | Non-employee directors shown with RSUs only in lifetime awards tally |
| Ownership as % of outstanding | ~0.0041% | 2,696 / 65,966,138 shares outstanding as of Mar 14, 2025 |
| Hedging/pledging | Prohibited | Insider Trading Policy bans hedging and pledging |
| Ownership guidelines | 5× annual cash retainer ($500,000) | Compliance required within 5 years; all non-employee directors in compliance or within phase-in |
Governance Assessment
- Board effectiveness: Independent director with deep pharma and Asia operating expertise; active MDC member; MDC employs independent consultant (Pay Governance); oversees CEO/NEO pay, succession, inclusion/equity/belonging; administers clawback policy; met 6 times in 2024—signals engagement .
- Compensation alignment (directors): Balanced cash/equity mix near market median; 2024 adjustments modest (+$10k equity for directors; chair retainer/equity increase); RSUs time-based under plan with best-practice provisions (no repricing; minimum vesting; dividend restrictions; director compensation cap) .
- Shareholder confidence: High say-on-pay approval (~97.4% in 2024) supports compensation governance credibility, albeit focused on executives rather than directors .
- Conflicts/related party: Xing’s external pharma roles (Mundipharma China) could present potential ecosystem overlap with Aptar Pharma; however, no related-person transactions disclosed; Audit Committee process and independence standards mitigate risk .
- RED FLAGS: None evident—no related-party transactions; no attendance shortfalls; hedging/pledging banned; director equity limits and clawback policies in force .
Key Policy References
- Insider Trading/Hedging & Pledging Prohibition
- Director Stock Ownership Guidelines (5× cash retainer; $500k)
- 2018 Equity Plan governance safeguards (min vesting; no repricing; director compensation limits; dividend restrictions; clawback)
Notes on Attendance and Engagement
- Board: 7 meetings in 2024; no director below 75% attendance .
- Executive sessions: Regular independent director sessions; chaired by independent Board Chair .
Director Compensation Summary (2024)
| Name | Cash Fees | Stock Awards | Total |
|---|---|---|---|
| Julie Xing | $107,000 | $160,072 | $267,072 |
Lifetime Director Awards Context
- Non-executive directors have been granted RSUs (aggregate 56,244); no options/SARs in director group lifetime tally—supports conservative director equity design .